In ’09 2009. From 1991 to 1998, Mr. Spiegelman served at Genentech, Inc., most recently as Treasurer. Mr. Spiegelman serves on the table of directors of Affymax also, Inc., Cyclacel Pharmaceuticals, Inc., Omeros Oncothyreon and Corporation, Inc., all publicly exchanged biopharmaceutical companies. Mr. Spiegelman retains a B.A. In economics from Stanford University and an M.B.A. From the Stanford Graduate College of Business. Resource Anthera Pharmaceuticals.. Anthera Pharmaceuticals reaches agreement with the FDA on SPA for VISTA-16 clinical study Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical firm developing drugs to treat serious diseases connected with inflammation, announced today that it reached an contract with the U.S.‘We are very happy to enroll the initial individual in the EVOLVE trial to judge this latest coronary stent technology,’ stated Prof. Meredith.’ ‘Although some companies remain evaluating their initial – or second-era drug-eluting stent technology, we are proud to begin with medical trials on our fourth-era stent,’ stated Keith Dawkins, M.D., Senior Vice President and Chief Medical Officer of Boston Scientific’s Cardiology, Vascular and Rhythm Group.’ ‘The SYNERGY Stent is made to combine the acute efficiency benefits of the platinum chromium PROMUS Component Stent with a forward thinking bioabsorbable polymer,’ stated Hank Kucheman, Executive Vice President and President of Boston Scientific’s Cardiology, Rhythm and Vascular Group.S., the SYNERGY Stent and the PROMUS Component Stent are investigational products and are tied to applicable laws to investigational only use and are unavailable for sale.